Veristat: Advancing Revolutionary Therapies (ART): Orphan Drug Designations and Orphan Subsets

Find out more now about US FDA’s Orphan Drug Designation (ODD) program, which qualifies sponsors for incentives including tax credits, exemption from user fees, and more. Learn more about which orphan subsets could qualify for ODD, in your free podcast episode